This study examined cases where patients receiving posaconazole to prevent fungal infections still developed serious mould infections despite the medication. Researchers compared 29 patients who developed these breakthrough infections with 46 control patients who did not. They found that over half of patients with breakthrough infections died, compared to only 20% of controls, and that surgical treatment significantly improved survival for certain types of fungal infections.